Results 51 to 60 of about 125,678 (274)

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Lewy Body Dementia Association\u27s Research Centers of Excellence Program: Inaugural Meeting Proceedings. [PDF]

, 2019
The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator\u27s meeting was held on December 14, 2017, in New Orleans.
Amodeo, Katherine, Armstrong, Melissa, Barrett, Matt, Boeve, Brad, Christie, Tina, Domoto-Reilly, Kimiko, Duda, John, Galasko, Douglas, Galvin, James E., Goldman, Jennifer, Gomperts, Stephen, Graff-Radford, Neill, Graham, Todd, Holden, Samantha, Honig, Lawrence, Huddleston, Daniel, Irwin, David, Kaufer, Daniel, Koehler, Mike, Leverenz, James, Lippa, Carol, Litvan, Irene, Lunde, Angela, Manning, Carol, Marder, Karen, McKeith, Ian G., Moussa, Charbel, Onyike, Chiadi, Pagan, Fernando, Pantelyat, Alexander, Paulson, Henry, Pelak, Victoria, Peterson, Bethany, Poston, Kathleen, Quinn, Joseph, Richard, Irene, Richards, Ian, Rosenthal, Liana S., Sabbagh, Marwan, Scharre, Douglas, Sha, Sharon, Shill, Holly, Siderowf, Andrew, Taylor, Angela, Torres-Yaghi, Yasar   +44 more
core   +3 more sources

Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the test performance of cutaneous phosphorylated alpha‐synuclein (P‐SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. Methods This is the first subgroup analysis of the Synuclein‐One study, a prospective, blinded study evaluating P‐SYN detection ...
Christopher H. Gibbons, Todd Levine, Charles H. Adler, Bailey Bellaire, Ningshan Wang, Pinky Agarwal, Georgina M. Aldridge, Alexandru Barboi, Daniel Claassen, Virgilio G. H. Evidente, Douglas Galasko, Alejandra Gonzalez‐Duarte, Ramon Gil, Mark Gudesblatt, Stuart H. Isaacson, Horacio Kaufmann, Pravin Khemani, Rajeev Kumar, Guillaume Lamotte, Andy J. Liu, Nikolaus R. McFarland, Mitchell G. Miglis, Adam Reynolds, Gregory A. Sahagian, Marie‐Helene Saint‐Hilaire, Julie B. Schwartzbard, Wolfgang Singer, Michael J. Soileau, Steven Vernino, Patricio Millar Vernetti, Oleg Yerstein, Roy Freeman   +31 more
wiley   +1 more source

Psychosocial Adjustment of In-Home Caregivers of Family Members with Dementia and Parkinson’s Disease: A Comparative Study

Parkinson's Disease, 2020
Neurodegenerative diseases such as Parkinson’s and dementia are highly prevalent worldwide. People who suffer from these disorders often receive in-home care and assistance from family members, who must dedicate a considerable amount of time to the care ...
María Cristina Lopes Dos Santos, María Victoria Navarta-Sánchez, José Antonio Moler, Ignacio García-Lautre, Sagrario Anaut-Bravo, Mari Carmen Portillo   +5 more
doaj   +1 more source

Use of a rivastigmine transdermic patch in Alzheimer's disease and Parkinson's disease dementia [PDF]

Romanian Journal of Neurology, 2009
Alzheimer’s disease and Parkinson’s disease dementia are becoming a public health issue. Given the therapeutic pitfalls in the elderly, there is a need of effective therapies. Rivastigmine, a cholinesterase inhibitor, emerges as an important agent in the
Lacramioara Perju Dumbrava, Teodor Fischer, Razvan Medrea   +2 more
doaj   +1 more source

Swallowing impairment in neurologic disorders : the role of videofluorographic swallowing study [PDF]

, 2018
Patients with neurologic diseases almost inevitably develop various degrees of swallowing disorders during their life. Dysphagia is one of the main negative prognostic factors in this class of patients, leading to severe morbidity (i.e.

core   +1 more source

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

COGNITIVE IMPAIRMENT AND DEMENTIA IN PARKINSON'S DISEASE

Актуальные проблемы теоретической и клинической медицины
Cognitive impairment is one of the most frequent and disabling non-motor manifestations of Parkinson's disease. It significantly reduces patients' quality of life, increases caregiver burden, and contributes to loss of independence.
A. Kondybayeva, S. Kamenova, K. Kuzhybayeva, D. Ospanbekova, S. Kenebayeva, K. Saduakasova, M. Zhanuzakov   +6 more
doaj   +1 more source

Luminescent conjugated oligothiophenes distinguish between α-synuclein assemblies of Parkinson’s disease and multiple system atrophy

Acta Neuropathologica Communications, 2019
Synucleinopathies [Parkinson’s disease with or without dementia, dementia with Lewy bodies and multiple system atrophy] are neurodegenerative diseases that are defined by the presence of filamentous α-synuclein inclusions.
Therése Klingstedt, Bernardino Ghetti, Janice L. Holton, Helen Ling, K. Peter R. Nilsson, Michel Goedert   +5 more
doaj   +1 more source

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia [PDF]

Journal of Movement Disorders, 2015
Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine ...
Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee   +2 more
doaj   +1 more source